Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
30 Jun 25
Updated
20 Aug 25
AnalystLowTarget's Fair Value
₹279.97
28.6% overvalued intrinsic discount20 Aug
₹359.95
1Y
1.9%7D
-1.2%